Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices: A 6-month, prospective, randomized, placebo-controlled, double-blind study
Tóm tắt
This study was undertaken to evaluate the effects of tibolone on abdominal subcutaneous fat, serum leptin levels (SLLs), and anthropometric indices, and to investigate potential relationships between SLLs, subcutaneous abdominal fat thickness, and anthropometric indices in postmenopausal women. In a 6-mo, prospective, randomized, double-blind, placebo-controlled study, 40 healthy postmenopausal women aged 42 to 67 y (mean: 50±4.7 y) were randomly assigned to 1 of 2 groups; during a 6-mo treatment period, the first group received tibolone (Livial® tablet; Organon, The Netherlands; 2.5 mg/d; n=19) and the other group was given placebo (n=21). Fasting SLLs determined by enzyme-linked immunosorbent assay, subcutaneous abdominal fat thickness assessed by ultrasound, and anthropometric indices of body weight, body mass index, waist and hip circumference, and waist-to-hip ratio (WHR) were recorded at the beginning and the end of the study. Statistical analyses were performed with Mann-Whitney, Wilcoxon, and Spearman tests.P values < .05 were considered significant. No significant differences between the 2 groups were reported in terms of all baseline characteristics. After 6 mo, body weight (+0.77±0.43 kg) and SLLs (+14.7±6.4 ng/mL) increased in the placebo control group, whereas waist circumference (-2.6±3.0 cm), hip circumference (-3.6±3.5 cm), and subcutaneous abdominal fat thickness (-4.3±4.8 cm) decreased significantly in the tibolone group (P < .05). At the end of the study, group comparisons revealed significant differences in waist and hip circumference and subcutaneous abdominal fat thickness (P < .05). At baseline, SLLs were correlated with subcutaneous abdominal fat thickness and all anthropometric indices except WHR (P < .05). Subcutaneous abdominal fat thickness was also highly correlated with all indices except WHR (P < .0001). Tibolone was found to decrease waist and hip circumference, as well as subcutaneous abdominal fat thickness. Also, tibolone appeared to attenuate weight gain and leptin increase. SLLs and subcutaneous abdominal fat thickness were positively correlated with all anthropometric indices except WHR.
Tài liệu tham khảo
Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.Br Med J. 1984; 289: 1257–1261.
Marin P, Andersson B, Ottosson M, et al. The morphology and metabolism of intraabdominal adipose tissue in men.Metabolism. 1992; 41: 1242–1248.
Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men.J Clin Invest. 1995; 96: 88–98.
Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat.Diabetes. 1997; 46: 1579–1585.
American Heart Association. Heart and stroke statistical update 2001: American Heart Association. Available at: http://216.185.102.50/statistics/. Accessed: May 1, 2006.
Gambacciani M, Ciaponi M, Cappagli B, Benussi C, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution.Climacteric. 1999; 2: 37–44.
Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study.Ann Intern Med. 1995; 123: 673–675.
Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish osteoporosis prevention study.J Bone Miner Res. 2003; 18: 333–342.
Ozbey N, Sencer E, Molvalilar S, Orhan Y. Body fat distribution and cardiovascular disease risk factors in pre- and postmenopausal obese women with similar BMI.Endocr J. 2002; 49: 503–509.
Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. The menopausal transition: a 9-year prospective population-based study. The Melbourne Women’s Midlife Health Project.Climacteric. 2004; 7: 375–389.
Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women.J Clin Endocrinol Metab. 1997; 82: 414–417.
Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.Cochrane Database Syst Rev. 2000; 2: CD001018.
Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.JAMA. 2002; 288: 321–333.
Rymer JM. The effects of tibolone.Gynecol Endocrinol. 1998; 12: 213–220.
Panidis DK, Rousso DH, Kourtis AI, Stergiopoulos KN, Mavromatidis GA, Katsikis IK. The influence of tibolone upon serum leptin levels in post-menopausal women.Eur J Obstet Gynecol Reprod Biol. 2001; 96: 85–87.
Lambrinoudaki IV, Christodoulakos GE, Panoulis CP, et al. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.Maturitas. 2004; 48: 107–113.
Gol M, Ozsener S, Sendag F, et al. Does tibolone affect serum leptin levels and body weight in postmenopausal women?Arch Gynecol Obstet. 2005; 272: 127–130.
Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat.Am J Clin Nutr. 2002; 75: 683–688.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue.Nature. 1994; 372: 425–432.
Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw IH. Clinical endocrinology of human leptin.Int J Obes Relat Metab Disord. 1999; 23: 29–36.
Wauters M, Mertens I, Considine R, De Leeuw I, Van Gaal L. Are leptin levels dependent on body fat distribution in obese men and women?Eat Weight Disord. 1998; 3: 124–130.
Isidori AM, Strollo F, More M, et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights.J Clin Endocrinol Metab. 2000; 85: 1954–1962.
Van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a predicted guide.Int J Obes Relat Metab Disord. 1993; 17: 187–196.
Armellini F, Zamboni M, Rigo L, et al. Sonography detection of small intra-abdominal fat variation.Int J Obes. 1991; 15: 847–852.
Campbell MK, Elbourne DR, Altman DG, CONSORT group. CONSORT statement: extension to cluster randomised trials.BMJ. 2004; 328: 702–708.
World Health Organization.Measuring Obesity-Classification and Description of Anthropometric Data. EUR/ICP/NUT 125–0612. Copenhagen: WHO Regional Office for Europe; 1988.
Yano K, Hosokawa K, Nakai K, Kubo T, Matsuo Y. Regional differences in ultrasonic assessment of subcutaneous fat thickness in the abdomen: effects on the TRAM flap.Ann Plast Surg. 2003; 51: 130–135.
Elbers JM, de Roo GW, Popp-Snijders C, et al. Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmenopausal women.Clin Endocrinol (Oxf). 1999; 51: 449–454.
Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women.J Endocrinol. 1999; 163: 55–62.
Vettor R, Vicennati V, Gambineri A, Pagano C, Calzoni F, Pasquali R. Leptin and the hypothalamicpituitary-adrenal axis activity in women with different obesity phenotypes.Int J Obes Relat Metab Disord. 1997; 21: 708–711.
Van Harmelen V, Reynisdottir S, Eriksson P, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women.Diabetes. 1998; 47: 913–917.
Pontiroli AE, Pizzocri P, Giacomelli M, et al. Ultrasound measurement of visceral and subcutaneous fat in morbidly obese patients before and after laparoscopic adjustable gastric banding: comparison with computerized tomography and with anthropometric measurements.Obes Surg. 2002; 12: 648–651.
Hirooka M, Kumagi T, Kurose K, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography.Intern Med. 2005; 44: 794–799.
Ribeiro-Filho FF, Faria AN, Azjen S, Zanella MT, Ferreira SR. Methods of estimation of visceral fat: advantages of ultrasonography.Obes Res. 2003; 11: 1488–1494.
Hanggi W, Lippuner K, Jaeger P, Birkhauser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.Clin Endocrinol (Oxf). 1998; 48: 691–699.
Arabi A, Garnero P, Porcher R, Pelissier C, Benhamou CL, Roux C. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study.Hum Reprod. 2003; 18: 1747–1752.
Meeuwsen IB, Samson MM, Duursma SA, Verhaar HJ. The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women.Endocrinology. 2001; 142: 4813–4817.
Boyanov MA, Shinkov AD. Effects of tibolone on body composition in postmenopausal women: a 1-year follow up study.Maturitas. 2005; 51: 363–369.
Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk.Am J Clin Nutr. 2004; 79: 379–384.